Why the study?
Chemotherapeutic drugs have improved cancer outcomes but caused an increasing incidence of cardiovascular complications, notably cardiotoxicity presenting as left ventricular systolic dysfunction.
Answers are grounded in this paper and cite their sources.
This review highlights the increasing incidence of cardiovascular side effects from chemotherapeutic drugs and discusses current treatment options and evidence gaps for cardiotoxicity.
Rapid advancements in oncological treatments over the past few decades have led to a significant improvement in cancer outcomes. Chemotherapeutic agents play a pivotal role in cancer treatment, with almost one-third of patients receiving them during their cancer treatment in the United Kingdom. The success of chemotherapeutic drugs has, however, resulted in an increasing incidence of cardiovascular side effects and complications. The most common cardiac manifestation is the development of cardiotoxicity, defined as the development of left ventricular systolic dysfunction, after treatment. This article provides an up-to-date review of the commonly used chemotherapeutic agents that cause cardiotoxicity and discusses current treatment options and evidence gaps.
No takes yet. Share an insight, caveat, or question.
A 2022 study studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: